Why the study?
Does radiofrequency renal denervation provide a cost-effective reduction in blood pressure and cardiovascular events compared to medication therapy alone in patients with uncontrolled hypertension in the US?
Does radiofrequency renal denervation provide a cost-effective reduction in blood pressure and cardiovascular events compared to medication therapy alone in patients with uncontrolled hypertension in the US?
Answers are grounded in this paper and cite their sources.
This editorial highlights a decision-analytic model demonstrating that radiofrequency renal denervation is a high-value, cost-effective intervention ($32,732 per QALY) for uncontrolled hypertension in the US health care system, though long-term outcome trials are still needed.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Lauder et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: